INSM - Insmed Inc Stock Analysis
Insmed Inc (INSM) is a publicly traded company listed on the NASD. It operates in the Biotechnology industry, part of the broader Healthcare sector. The company has a market capitalization of 31.66B, generates annual revenue of 447.02M, and reports net income of -1.18B. As of the latest data, the stock is trading at 148.43 USD.
From a valuation and risk perspective, the stock presents the following profile: The P/E ratio is unavailable or not meaningful at this time. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. This stock does not currently pay a dividend. The stock has average market volatility, aligning with general market movement.
Analyst recommendation stands at Buy (4.26), indicating current market sentiment. Institutional ownership is reported at 103.59%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 85.79%, trading within a 52-week range of 60.40 - 212.75.
INSM - Insmed Inc
148.43
Analyst Consensus
Buy 4.26
INSM – Analyst Rating Summary
- Strong Buy: 9
- Buy: 16
- Hold: 2
- Sell: 0
- Strong Sell: 0
- Total Analysts: 27
| Index: | NDX | P/E: | - | EPS (ttm): | -6.18 | Insider Own: | 1.37% | Shs Outstand: | 212.58M | Perf Week: | -2.63% |
| Market Cap: | 31.66B | Forward P/E: | - | EPS next Y: | -2.46 | Insider Trans: | -21.20% | Shs Float: | 210.34M | Perf Month: | -11.50% |
| Income(ttm): | -1.18B | PEG: | - | EPS next Q: | -1.06 | Inst Own: | 103.59% | Short Float: | 5.56% | Perf Quarter: | -22.66% |
| Revenue(ttm): | 447.02M | P/S: | 70.82 | EPS this Y: | -4.66% | Inst Trans: | 0.94% | Short Ratio: | 3.85 | Perf Half Y: | 21.66% |
| Book/sh: | 4.45 | P/B: | 33.37 | EPS next Y: | 57.75% | ROA: | -53.64% | Short Interest: | 11.70M | Perf Year: | 85.79% |
| Cash/sh: | 7.88 | P/C: | 18.84 | EPS next 5Y: | - | ROE: | -165.69% | 52W Range: | 60.40 - 212.75 | Perf YTD: | -14.72% |
| Dividend Est.: | - | P/FCF: | - | EPS past 3/5Y: | -12.84% -13.12% | ROIC: | -70.54% | 52W High: | 212.75 -30.23% | Beta: | 1.13 |
| Dividend TTM: | - | Quick Ratio: | 4.34 | Sales past 3/5Y: | 24.50% 21.66% | Gross Margin: | 75.35% | 52W Low: | 60.40 145.75% | Perf 5Y: | 267.95% |
| Dividend Ex-Date: | - | Current Ratio: | 4.63 | EPS Y/Y TTM: | -11.26% | Oper. Margin: | -221.53% | RSI (14): | 33.31 | Volatility: | 3.35% 3.98% |
| Employees: | 1271 | Debt/Eq: | 0.79 | Sales Y/Y TTM: | 30.34% | Profit Margin: | -264.83% | Recom: | 1.18 | Target Price: | 215.15 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.77 | EPS Q/Q: | -37.66% | Payout: | - | Rel Volume: | 0.48 | Prev Close: | 148.55 |
| Sales Surprise: | 23.30% | EPS Surprise: | -31.72% | Sales Q/Q: | 52.36% | Earnings: | Feb 19 BMO | Avg Volume: | 3.04M | Price: | 148.43 |
| SMA20: | -4.99% | SMA50: | -14.52% | SMA200: | 7.92% | Undervalued: 44.95% | Volume: | 1,462,803 | Change: | -0.08% | |
Graham Classic formula value: -47.17
(P/E=8 * 1g) Min value: -44.4
(current P/E * 2g) Max value: -0.0
Average value: -30.52
About Insmed Inc
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.